Phase 3 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with Stage I to Stage IV prostate cancer that has not spread to the bones (involvement of lymph nodes is allowed, and a previous diagnosis of another cancer is also allowed)
- People aged 50 years or older
- People who are about to start, or have recently started, a hormone treatment called ADT (androgen deprivation therapy) within the past 6 months, with at least 6 months of that treatment planned in total
- People whose blood vitamin D level falls between 10 and 32 ng/ml (a specific range checked by a blood test)
- People whose blood calcium level is 10.5 mg/dl or below
- People whose kidneys are functioning at a normal filtering rate (a blood test result above 30 ml/min)
- People who agree not to take their own calcium or vitamin D supplements during the trial, other than those supplied by the study
- People who are able to give written consent to participate
- People who are able to swallow pills and capsules
- People who are able to speak and read English
Who may not be able to join:
- People who have used bone-strengthening medications (such as bisphosphonates, denosumab, or teriparatide) for more than 3 months before joining the trial
- People who have been diagnosed with Stage IV (late-stage) chronic kidney disease
- People whose blood calcium level is above 11.5 mg/dl (a condition called high-grade hypercalcemia)
- People who have a history of abnormally high calcium levels, or who have previously had a bad reaction to or poisoning from vitamin D
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Reduction of bone mineral density (BMD) loss as measured at the total hip; Reduction of BMD loss as measured at the femoral neck; Reduction of BMD loss as measured at the distal radius; Reduction of BMD loss as measured at the lumbar spine
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.